Eisele Jeffrey
SEC insider (Form 3/4/5 filer). CIK 0001827326. Chief Development Officer at Apellis Pharmaceuticals, Inc. (APLS). 4 reported Form 4/5 transactions since Sep 2024; latest on Jan 29, 2025. Located in WALTHAM, MA.
Companies Eisele Jeffrey has filed insider reports for
- Apellis Pharmaceuticals, Inc. (APLS): Officer, Chief Development Officer
Eisele Jeffrey
CIK: 0001827326
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)4 (100.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)0 (0.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
APLS
Apellis Pharmaceuticals, Inc.
Officer
Discretionary Trading P&L
Holdings
Transaction History (4 total)
- Jan 29, 2025APLS
Apellis Pharmaceuticals, Inc.
SaleDirect278 shares at avg. $29.52$8K - Jan 22, 2025APLS
Apellis Pharmaceuticals, Inc.
SaleDirect1.3K shares at avg. $30.43$39K - Jan 13, 2025APLS
Apellis Pharmaceuticals, Inc.
SaleDirect264 shares at avg. $28.70$8K - Dec 23, 2024APLS
Apellis Pharmaceuticals, Inc.
SaleDirect63 shares at avg. $33.09$2K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jan 29, 2025 | APLS Apellis Pharmaceuticals, Inc. | Sale | 278 | $29.52 | $8,208 | Direct |
| Jan 22, 2025 | APLS Apellis Pharmaceuticals, Inc. | Sale | 1,291 | $30.43 | $39,279 | Direct |
| Jan 13, 2025 | APLS Apellis Pharmaceuticals, Inc. | Sale | 264 | $28.70 | $7,577 | Direct |
| Dec 23, 2024 | APLS Apellis Pharmaceuticals, Inc. | Sale | 63 | $33.09 | $2,085 | Direct |
1-4 of 4 transactions